News

16 November 2022

Figures of Indonesia Indigenous Modern Medicine Receive Honorary Title of Adjunct Professorship from Atma Jaya Catholic University

Dr. Raymond Rubianto Tjandrawinata, a leading figure in Indonesia Indigenous Modern Medicine (OMAI), was awarded the honorary title of Adjunct Professor in Pharmaceutical Biotechnology by the Indonesian Catholic University (Unika) Atma Jaya Jakarta. Dr. Raymond Rubianto Tjandrawinata has demonstrated a scientific discovery and contribution to the advancement of pharmaceutical biotechnology,…
9 November 2022

Dexa Group Leader's Public Lecture at Sanata Dharma University: Building Independence as a Dexa Group Contribution

Mr. Ferry Soetikno, the leader of the Dexa Group, served as a speaker during the Sanata Dharma University Yogyakarta Public Lecture. During his guest lecture, Mr. Ferry covered two subjects for hundreds of University of Sanata Dharma students and graduates: the introduction of Dexa Medica and the independence of pharmaceuticals…
4 November 2022

Dexa Group's Strategic Support for Indonesian Pharmacy Resilience and Independence: Indonesia Indigenous Modern Medicine Phytopharmaceutical

The pharmaceutical business is still working toward independence and health security due to the changes in the market brought on by the pandemic circumstances, the global financial crisis, and the high US Dollar exchange rate against the Rupiah. Dexa Group presented three significant initiatives for pharmaceutical resilience and independence with…
1 September 2022

More Than 17 Years Trusted by Indonesian Families, STIMUNO Wins Indonesian Mom's Favorite Brand Choice Awards 2022

For more than 17 years, STIMUNO, the first phytopharmaca immunomodulator in Indonesia, had been relied on by the Indonesian Family to support the health of their immune systems. For this accomplishment, STIMUNO earned the Top 5 Indonesian Mom's Favorite Brands for Multivitamin Category in the Household & Personal Care (non-food)…
26 August 2022

Supporting Making Indonesia 4.0, Dexa Group Through Ferron Par Pharmaceuticals Accelerates The Implementation of Industry 4.0

Indonesia's Ministry of Industry accelerates seven industrial sectors, including pharmaceuticals, in implementing the Making Indonesia 4.0 roadmap to make Indonesia the top 10 big countries with the most robust economy globally by 2030. In line with this effort, as Indonesia's leading international pharmaceutical company, Dexa Group has implemented industry 4.0…
24 August 2022

Dexa Group Consistently Maintains Natural Ingredient Quality for Indonesian Phytopharmaceutical Products

Dexa Group, as a national pharmaceutical company, is committed to meeting the quality of Indonesian natural raw materials as the content of Indonesian Indigenous Modern Medicines, beginning with cultivation, harvesting, and post-harvest processes and continuing through the manufacturing process by Good Traditional Medicine Manufacturing standards (CPOTB). This is necessary to…
12 August 2022

The Ministry of Health Continues to Encourage the Use of Phytopharmaceuticals in Health Service Facilities

The government primarily focuses on developing phytopharmaceuticals to create a system of health resilience and domestic pharmaceutical self-reliance. Launching the Phytopharmaca Formulary and promoting its usage in medical institutions are examples of the government's commitment to fostering the use of phytopharmaceuticals. The Director General of Pharmaceuticals and Medical Devices at…
5 August 2022

Dexa Group's Commitment to Encourage the Production of Natural Medicine Raw Materials for National Independence

With more than 28000 plant species and 2,848 medicinal plants, Indonesia has the second-highest biodiversity in the world. Its natural resources hold tremendous promise for developing phytopharmaceuticals and herbal medicines, including Indonesia Indigenous Modern Medicine (IIMM). Penny K. Lukito, head of the Food and Drug Supervisory Agency (BPOM), stated that…
1 August 2022

Dexa Award Science Scholarship 2022 Stimulates Innovation to Build Health Independence

The Indonesian government continues to encourage the resilience and independence of the healthcare industry, as imports dominate 90% of its domestic pharmaceutical raw materials and health spending. In addition, 88% of medical device transactions through electronic catalogs (e-catalogs) are imported products. Meanwhile, research and development funds are only about 0.2%…
8 July 2022

Prevent Stunting, Dexa Group's Green Pharmacy Becomes The Partner of BKKBN

Indonesia's 29th National Family Day (Harganas) was celebrated with the theme "Let's Prevent Stunting for Stunting-Free Family". President Joko Widodo (Jokowi) said that the government had appointed the National Population and Family Planning Agency (BKKBN) to reduce the prevalence of stunting to 14% in 2024. Therefore, BKKBN collaborates with several…